secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2023-04-10T23:59:59+00:00
Accession:  0001213900-23-028383
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Therapeutics amends reverse stock split ratio range to 1-for-2 to 1-for-20
--------------------------------------------------------------------------------

- Amendment No. 1 changes the reverse stock split ratio range from 1-for-10–1-for-20 to 1-for-2–1-for-20.
- The amendment modifies Section 4.16(iii) of the Securities Purchase Agreement dated March 3, 2023.
- Company will seek stockholder approval of the revised reverse split range at the upcoming annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023028383/0001213900-23-028383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023028383/ea176728-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-028383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer